{{Rsnum
|rsid=2868177
|Gene=POR
|Chromosome=7
|position=75960585
|Orientation=plus
|GMAF=0.421
|Gene_s=POR
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 40.7 | 48.7 | 10.6
| HCB | 26.3 | 54.7 | 19.0
| JPT | 24.8 | 54.9 | 20.4
| YRI | 36.7 | 51.7 | 11.6
| ASW | 26.3 | 63.2 | 10.5
| CHB | 26.3 | 54.7 | 19.0
| CHD | 32.1 | 50.5 | 17.4
| GIH | 57.4 | 36.6 | 5.9
| LWK | 25.5 | 42.7 | 31.8
| MEX | 22.4 | 44.8 | 32.8
| MKK | 23.1 | 53.2 | 23.7
| TSI | 39.2 | 43.1 | 17.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=22719896
|Title=Influence of Various Polymorphic Variants of Cytochrome P450 Oxidoreductase (POR) on Drug Metabolic Activity of CYP3A4 and CYP2B6
|OA=1
}}

{{PMID Auto
|PMID=21562147
|Title=Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.
|OA=1
}}

{{PMID Auto
|PMID=24273552
|Title=A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}